Identification of Signal Pathways and Hub Genes of Pulmonary Arterial Hypertension by Bioinformatic Analysis
- PMID: 36072642
- PMCID: PMC9444450
- DOI: 10.1155/2022/1394088
Identification of Signal Pathways and Hub Genes of Pulmonary Arterial Hypertension by Bioinformatic Analysis
Abstract
Pulmonary arterial hypertension (PAH) is a progressive and complex pulmonary vascular disease with poor prognosis. The aim of this study was to provide a new understanding of the pathogenesis of disease and potential treatment targets for patients with PAH based on multiple-microarray analysis.Two microarray datasets (GSE53408 and GSE113439) downloaded from the Gene Expression Omnibus (GEO) database were analysed. All the raw data were processed by R, and differentially expressed genes (DEGs) were screened out by the "limma" package. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed and visualized by R and Cytoscape software. Protein-protein interactions (PPI) of DEGs were analysed based on the NetworkAnalyst online tool. A total of 442 upregulated DEGs and 84 downregulated DEGs were identified. GO enrichment analysis showed that these DEGs were mainly enriched in mitotic nuclear division, organelle fission, chromosome segregation, nuclear division, and sister chromatid segregation. Significant KEGG pathway enrichment included ribosome biogenesis in eukaryotes, RNA transport, proteoglycans in cancer, dilated cardiomyopathy, rheumatoid arthritis, vascular smooth muscle contraction, focal adhesion, regulation of the actin cytoskeleton, and hypertrophic cardiomyopathy. The PPI network identified 10 hub genes including HSP90AA1, CDC5L, MDM2, LRRK2, CFTR, IQGAP1, CAND1, TOP2A, DDX21, and HIF1A. We elucidated potential biomarkers and therapeutic targets for PAH by bioinformatic analysis, which provides a theoretical basis for future study.
Copyright © 2022 Rui-Qi Wei et al.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Figures




Similar articles
-
Integrated Bioinformatics Analysis Reveals Marker Genes and Potential Therapeutic Targets for Pulmonary Arterial Hypertension.Genes (Basel). 2021 Aug 28;12(9):1339. doi: 10.3390/genes12091339. Genes (Basel). 2021. PMID: 34573320 Free PMC article.
-
Identification of hub genes based on integrated analysis of single-cell and microarray transcriptome in patients with pulmonary arterial hypertension.BMC Genomics. 2023 Dec 18;24(1):788. doi: 10.1186/s12864-023-09892-3. BMC Genomics. 2023. PMID: 38110868 Free PMC article.
-
Identification of TFRC as a biomarker for pulmonary arterial hypertension based on bioinformatics and experimental verification.Respir Res. 2024 Aug 3;25(1):296. doi: 10.1186/s12931-024-02928-6. Respir Res. 2024. PMID: 39097701 Free PMC article.
-
Identification of novel biomarkers involved in pulmonary arterial hypertension based on multiple-microarray analysis.Biosci Rep. 2020 Sep 30;40(9):BSR20202346. doi: 10.1042/BSR20202346. Biosci Rep. 2020. PMID: 32886110 Free PMC article.
-
The identification and verification of hub genes associated with pulmonary arterial hypertension using weighted gene co-expression network analysis.BMC Pulm Med. 2022 Dec 13;22(1):474. doi: 10.1186/s12890-022-02275-6. BMC Pulm Med. 2022. PMID: 36514015 Free PMC article.
Cited by
-
Molecular Mechanisms Underlying the Progression of Aortic Valve Stenosis: Bioinformatic Analysis of Signal Pathways and Hub Genes.Int J Mol Sci. 2023 Apr 27;24(9):7964. doi: 10.3390/ijms24097964. Int J Mol Sci. 2023. PMID: 37175670 Free PMC article.
-
NCAPG Promotes Pulmonary Artery Smooth Muscle Cell Proliferation as a Promising Therapeutic Target of Idiopathic Pulmonary Hypertension: Bioinformatics Analysis and Experiment Verification.Int J Mol Sci. 2022 Oct 4;23(19):11762. doi: 10.3390/ijms231911762. Int J Mol Sci. 2022. PMID: 36233060 Free PMC article.
-
Expression Profiles of circRNAs and Identification of hsa_circ_0007608 and hsa_circ_0064656 as Potential Biomarkers for COPD-PH Patients.Int J Chron Obstruct Pulmon Dis. 2023 Nov 7;18:2457-2471. doi: 10.2147/COPD.S424712. eCollection 2023. Int J Chron Obstruct Pulmon Dis. 2023. PMID: 37955024 Free PMC article.
-
Serum proteome profiling reveals HGFA as a candidate biomarker for pulmonary arterial hypertension.Respir Res. 2024 Nov 28;25(1):418. doi: 10.1186/s12931-024-03036-1. Respir Res. 2024. PMID: 39609799 Free PMC article.
-
Network pharmacology and molecular docking: combined computational approaches to explore the antihypertensive potential of Fabaceae species.Bioresour Bioprocess. 2024 May 20;11(1):53. doi: 10.1186/s40643-024-00764-6. Bioresour Bioprocess. 2024. PMID: 38767701 Free PMC article.
References
-
- Kim D., George M. P. Pulmonary hypertension. Medical Clinics of North America . 2019;103(3):413–423. - PubMed
-
- Galie N., Humbert M., Vachiery J. L., et al. Esc/ers guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (esc) and the European respiratory society (ers): endorsed by: association for European paediatric and congenital cardiology (aepc), international society for heart and lung transplantation (ishlt) European Heart Journal . 2015;37(1):67–119. doi: 10.1093/eurheartj/ehv317. - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous